

Please type a plus sign (+) inside this box →

PTO/SB/05 (12/97) Approved for use through 09/30/00 OMB 0651-0032

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

# UTILITY PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No. 10690/T/B/A Total Pages

First Named Inventor or Application Identifier

Berend Houwen

Express Mail Label No. EM352400262US

## APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1.  Fee Transmittal Form  
(Submit an original, and a duplicate for fee processing)
2.  Specification Total Pages 23  
(preferred arrangement set forth below)
  - Descriptive title of the Invention
  - Cross References to Related Applications
  - Statement Regarding Fed sponsored R & D
  - Reference to Microfiche Appendix
  - Background of the Invention
  - Brief Summary of the Invention
  - Brief Description of the Drawings (if filed)
  - Detailed Description
  - Claim(s)
  - Abstract of the Disclosure
3.  Drawing(s) (35 USC 113) Total Sheets 7
4. Oath or Declaration Total Pages
  - a.  Newly executed (original or copy)
  - b.  Copy from a prior application (37 CFR 1.63(d))  
(for continuation/divisional with Box 17 completed)  
[Note Box 5 below]
    - i.  DELETION OF INVENTOR(S)  
Signed statement attached deleting  
inventor(s) named in the prior application,  
see 37 CFR 1.63(d)(2) and 1.33(b).
5.  Incorporation By Reference (useable if Box 4b is checked)  
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

ADDRESS TO: Assistant Commissioner for Patents  
Box Patent Application  
Washington, DC 20231

6.  Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission  
(if applicable, all necessary)
  - a.  Computer Readable Copy
  - b.  Paper Copy (identical to computer copy)
  - c.  Statement verifying identity of above copies

## ACCOMPANYING APPLICATION PARTS

8.  Assignment Papers (cover sheet & document(s))
9.  37 CFR 3.73(b) Statement  Power of Attorney  
(when there is an assignee)
10.  English Translation Document (if applicable)
11.  Information Disclosure Statement (IDS)/PTO-1449  Copies of IDS Citations
12.  Preliminary Amendment
13.  Return Receipt Postcard (MPEP 503)  
(Should be specifically itemized)
14.  Small Entity  Statement filed in prior application,  
Statement(s)  Status still proper and desired
15.  Certified Copy of Priority Document(s)  
(if foreign priority is claimed)
16.  Other: .....

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

Continuation  Divisional  Continuation-in-part (CIP) of prior application No: \_\_\_\_\_ / \_\_\_\_\_

## 18. CORRESPONDENCE ADDRESS

Customer Number or Bar Code Label or  Correspondence address below

(Insert Customer No. or Attach bar code label here)

NAME	Maurice B. Stiefel, Esq.				
	BRYAN CAVE LLP				
ADDRESS	245 Park Avenue				
	CITY		STATE	ZIP CODE	10167
COUNTRY	US	TELEPHONE	(212) 692-1800	FAX	(212) 692-1900

Burden Hour Statement: This form is estimated to take 0 2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.

Assistant Commissioner for Patents  
Box Patent Application  
Washington, D.C. 20231

Sir:

Transmitted herewith for filing is the utility patent application of Inventor(s):

For: **METHOD FOR CLASSIFYING AND COUNTING LEUKOCYTES**

1.  The application has 23 pages (including claim pages, and abstract).
2.  7 sheets of drawing are enclosed. The drawings are:
  - a.  formal; or
  - b.  informal; formal drawings will be submitted in due course.
3.  The declaration and power of attorney
  - a.  has been executed by all the inventors; or
  - b.  has not been executed by all the inventors. A signed declaration and power of attorney will be submitted in due course.
4.  An associate power of attorney is enclosed.
5.  An assignment of the invention to \_\_\_\_\_ and a Recordation Form Cover are enclosed. Please record the Assignment and return it to the undersigned. A duplicate copy of this paper is enclosed.
  - a.  A check for \$40.00 to cover the recording fee is enclosed. See paragraph 10.c., below.
  - b.  Please charge the recording fee to our Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
6.  Priority is hereby claimed under 35 USC 119 based on Appln. No. \_\_\_\_\_, filed \_\_\_\_\_, 19\_\_\_\_\_, in the European Patent Office.
  - a.  A certified copy of each of the priority documents is enclosed.
  - b.  The certified priority document(s) will follow.
7.  A verified statement to establish small entity status under 37 CFR Section 1.9 and 37 CFR Section 1.27 is enclosed.
8.  The filing fee is calculated below.

For	Col. 1 No. Filed		Col. 2 No. Extra	Small Entity Rate Fee	or	Other Than A Small Entity Rate Fee
Basic Fee:				\$ 385	or	\$ 760
Total Claims:	11-20=	x		x11=	or	x18=
Indep. Claims	1 - 3=	x		x40=	or	x78=
[ ] Multiple Dependent Claims Presented				+ 130 =	or	+ 260 =
Total: \$760.00						

\*If the difference in Col. 1 is less than zero, enter "0" in Col. 2.

- a.  A check for \$760.00 to cover the filing fee is enclosed. See paragraph 10a and 10d, below.
- b.  Please charge Deposit Account No. 02-4467 in the amount of \$\_\_\_\_\_. A duplicate copy of this paper is enclosed.
- 9.  A Preliminary Amendment is enclosed.
  - a.  No additional fee is due.
  - b.  A check in the amount of \$\_\_\_\_ to cover the cost of additional claims is enclosed. See paragraph 10.a., below.
  - c.  Please charge our Deposit Account 02-4467 in the amount of \$\_\_\_\_\_. A duplicate copy of this paper is enclosed.
- 10.  The Commissioner is hereby authorized to charge payment of the following fees associated with this application or with recording any Assignment concerning it, or to credit any overpayment, to Deposit Account No. 02-4467, unless otherwise paid by check.
  - a.  If our check is missing or otherwise insufficient, or if any additional fees are required, the Commissioner is authorized to charge (or credit any overpayment) to Deposit Account No. 02-4467. A duplicate copy of this paper is enclosed.
  - b.  Any additional filing or other fees required under 37 CFR Section 1.16, including any fees for presentation of extra claims.
  - c.  Any patent application processing fees under 37 CFR Section 1.17.
  - d.  Any additional Assignment recording fees under 37 CFR Section 1.21(h).


Note: See 37 CFR ' 1.311(b) regarding authorization to pay the issue fee from deposit account.

- c. [x] Any patent application processing fees under 37 CFR Section 1.17.
- d. [x] Any additional Assignment recording fees under 37 CFR Section 1.21(h).

Note: See 37 CFR ' 1.311(b) regarding authorization to pay the issue fee from deposit account.

- 11. [x] An Information Disclosure Statement is enclosed.

Respectfully submitted,

By:   
Maurice B. Stiefel  
Registration No. 14,879  
BRYAN CAVE LLP  
245 Park Avenue  
New York, NY 10167-0034  
Tel. (212) 692-1800  
Fax (212) 692-1900

66/20/60  
JULY 14 1999  
U.S. PATENT & TRADEMARK OFFICE

A

Docket No.: 10690/T/B/A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

09/366,699  
JULY 14 1999  
U.S. PATENT & TRADEMARK OFFICE

In re Patent Application of: )  
                                  )  
Berend Houwen, Fu-sheng Wang, Hiroyuki Fujimoto, )  
Takashi Sakata, and Yukio Hamaguchi                   )  
                                  )  
Filed Concurrently Herewith On September 1, 1999   )

For: **METHOD FOR CLASSIFYING AND COUNTING LEUKOCYTES**

**CERTIFICATE OF EXPRESS MAILING**

"Express Mail" Mailing Label No.: EM352400262US

Date of Deposit: September 2, 1999

I hereby certify that the following:

- This Certificate of Express Mailing
- Utility Patent Application Transmittal - Form PTO/SB/05 (1 p.)
- Letter of Transmittal of Utility Patent Application (3 pp. in duplicate)
- Original Patent Application (23 pp.)
- Fee Transmittal Form (1 p.)
- Check in the amount of \$760.00 for filing fee of patent application
- 7 Sheets of Informal Drawings
- Information Disclosure Statement (2 pp.)
- Form PTO-1449 (1 p.)
- References cited in the Information Disclosure Statement
- Return postcard

are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR Section 1.10 on the Date of Deposit indicated above in an envelope addressed to the Box Patent Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

  
\_\_\_\_\_  
DARRYL TERRELL

BRYAN CAVE LLP  
245 Park Avenue  
New York, New York 10167-0034  
212/692-1800

## **TITLE OF THE INVENTION**

### **METHOD FOR CLASSIFYING AND COUNTING LEUKOCYTES**

## **BACKGROUND OF THE INVENTION**

### **1. Field of the Invention**

5 The present invention relates to a method for classifying and counting leukocytes, more particularly a method for classifying and counting leukocytes which allows immature granulocytes different in degree of maturity to be classified and counted by a flow cytometry.

### **10 2. Description of Related Art**

In the field of clinical examination, classifying and countering immature granulocytes according to the degree of maturity is advantageous since it provides significantly useful information for making a correct diagnosis of a disease and for

### **15 observing the course of a disease.**

For example, immature granulocytes normally exist in bone marrow but do not exist in peripheral blood. For this reason, the presence of immature granulocytes in peripheral blood of a patient indicates the possibility that the patient has an infectious disease, 20 inflammatory disease, chronic or acute myelocytic leukemia, malignant tumor or other disease. Accordingly, classifying and enumerating immature granulocytes different in the degree of maturity is helpful for diagnosing these diseases and for monitoring the progress of the diseases.

25 Conventionally, a common method for classifying and

counting immature granulocytes is comprised of preparing a smear sample of blood, staining the sample with a suitable dye, microscopically classifying cells in the sample into categories of promyelocytes, myelocytes and metamyelocytes according to their 5 degree of maturity, and counting cells in each category. However, this method requires a complicated pretreatment before microscopic observation. Accuracy of the method is poor because only a limited number of cells can be counted. Furthermore, considerable skill of the operator is required for accurate classification. Reproducibility 10 is limited due to the small number of leukocytes enumerated.

On the other hand, a variety of methods utilizing the principle of flow cytometry have been proposed for analysis of blood components in marrow fluid which contains blood cells in various stages of maturity.

15 For example, U.S. Patent No.5,137,809 has proposed a method for identifying different cell series and stages of maturity of cells in marrow fluid using a first antibody for indicating leukocytes and a second antibody for classifying leukocytes into sub- populations. However, this method has a problem in that 20 immature granulocytes cannot be classified according to their degree of maturity as by microscopic observation, because the stages of maturity are indicated only by one parameter, i.e., the second antibody.

Bowen et al have reported that the intensity of expression of 25 CD16 and CD11b reflects the degree of maturity of granulocytic cells

in bone marrow (Abnormal patterns of expression of CD16(FcRgIII) and CD11b(CRIII) antigens by developing neutrophils in the bone marrow of patients with myelodysplastic syndrome (Laboratory Hematology, Vol.3, No.4, 292 to 298, 1997)). According to this

5 report, granulocytic cells are first indicated with CD45 and SSC (side scattered light) and the degree of maturity of the granulocytic cells can be judged by checking the intensity of expression of CD16 and CD11b in the granulocytic cells. However, this method cannot distinguish mature eosinophils from immature granulocytes and 10 therefore analysis results are poor. Particularly, both mature eosinophils and immature granulocytes are CD16-negative and CD11b-negative and cannot be separated from each other.

For analyzing leukocyte components in a sample of peripheral blood, a variety of methods have been proposed.

15 For example, U.S. Patent No. 5,413,938 has proposed a method for measuring immature granulocytes by lysing mature leukocytes with a reagent containing a nonionic surfactant and an amino acid. However, according to this method, all leukocytes except immature granulocytes are lysed and thus cannot be 20 enumerated. Therefore, this method alone cannot calculate the ratio of an immature granulocyte count to a leukocyte count.

Hübl et al have reported a method for detecting immature neutrophils on the basis of expression of CD16 (Value of neutrophil CD16 expression for detection of left shift and acute-phase 25 response; Am. J. Clin. Pathol., 107(2): 187-196, Feb. 1997).

However, this method does not describe a method for classifying immature granulocytes according to the degree of maturity.

Under these circumstances, there is a demand for a method for accurately counting immature granulocytes in peripheral blood

5 independently of effect of other leukocytic cells and classifying the immature granulocytes according to their degree of maturity.

## **SUMMARY OF THE INVENTION**

The present invention provides a method for classifying and counting leukocytes comprising the steps of:

10 (1) adding to a hematological sample the following fluorescence-labeled antibodies labeled with fluorescent dyes which emit fluorescences distinguishable from each other;

15 (a) a first fluorescence-labeled antibody which bonds specifically to leukocytes,

(b) a second fluorescence-labeled antibody which bonds to at least one kind of neutrophilic cells, and

15 (c) a third fluorescence-labeled antibody which bonds to at least one kind of immature granulocytic cells,

20 in order to stain leukocytic cells in the hematological sample, and

removing erythrocytes from the hematological sample;

25 (2) analyzing the resulting hematological sample using a flow cytometer to measure at least one scattered light signal and three separate fluorescence signals;

(3) defining a group of granulocytic cells on the basis of

intensity of the scattered light and intensity of fluorescence from the first fluorescence-labeled antibody;

5 (4) defining neutrophilic cells in the defined group of granulocytic cells on the basis of the intensity of the fluorescence from the first fluorescence-labeled antibody and intensity of fluorescence from the second or third fluorescence-labeled antibody;

10 (5) classifying the defined group of the neutrophilic cells into groups of neutrophilic cells different in degree of maturity on the basis of the intensity of the fluorescence from the second fluorescence-labeled antibody and the intensity of the fluorescence from the third fluorescence-labeled antibody, and

15 counting the number of cells in each of the groups different in the degree of maturity.

20 These and other objects of the present application will become more readily apparent from the detailed description given below. However, it should be understood that the detailed description and specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25 Fig. 1 is a scattergram for identifying the whole leukocyte group;

Fig. 2 is a scattergram for identifying granulocytes only

(neutrophils and eosinophils);

Fig. 3 is a scattergram for identifying neutrophilic cells only;

Fig. 4 is a scattergram for identifying immature  
5 granulocytes;

Fig. 5 is a scattergram for identifying groups of immature  
granulocytes different in degree of maturity;

Fig. 6 is a scattergram showing distribution of individual  
cells with intensities of side scattered light and red fluorescence  
10 plotted in coordinate axes in accordance with Example 1;

Fig. 7 is a scattergram showing distribution of all  
leukocytes and granulocytic cells (neutrophilic cells and  
eosinophils) in accordance with Example 1;

Fig. 8 is a scattergram showing distribution of eosinophils,  
15 immature granulocytes and mature neutrophils with intensities of  
red and green fluorescence plotted in the coordinate axes in  
accordance with Example 1;

Fig. 9 is a scattergram showing distribution of stage-I  
immature granulocytes, stage-II immature granulocytes and mature  
20 neutrophils with orange and green fluorescence plotted in the  
coordinate axes in accordance with Example 1;

Fig. 10 is a graph showing correlation between an immature  
granulocyte count by the method of the present invention and that  
by a manual method;

25 Fig. 11 is a scattergram showing distribution of stage-I

immature granulocytes, stage-II immature granulocytes and mature neutrophils with orange and green fluorescence plotted in the coordinate axes in accordance with Example 2;

Fig. 12 is a graph showing correlation between the stage-I 5 immature granulocyte count by the method of the present invention and that by the a manual method;

Fig. 13 is a graph showing correlation between the stage-II immature granulocyte count by the method of the present invention and that by the manual method.

## 10 **DESCRIPTION OF THE PREFERRED EMBODIMENTS**

In the present invention, the hematological sample used in step (1) means a sample of body fluid such as peripheral blood, bone marrow fluid, urine or a sample collected by apheresis, of a mammal, especially a human. Such hematological samples may be subjected 15 to the steps of the present invention either directly after being collected or after heparin or other anticoagulant is added thereto in an appropriate amount, for example.

The type of the antibody of the first fluorescence-labeled antibody which bonds specifically to leukocytic cells is not 20 particularly limited provided that it bonds specifically to various kinds of leukocytes, such as monocytes, lymphocytes, neutrophils, eosinophils and basophils. For example, an anti-CD45 antibody may be mentioned. As this antibody, a commercially available one may be used.

25 The antibody of the second fluorescence-labeled antibody

which bonds to neutrophilic cells is an antibody capable of recognizing an antigen which exists on the surface of neutrophilic cells in varying densities depending upon the degree of maturity of the neutrophilic cells and bonding to the neutrophilic cells. The type 5 of the antibody is not particularly limited, provided that it bonds to one kind of or two or more kinds of promyelocytes, myelocytes, metamyelocytes, band forms, segmented forms and the like. For example, an anti-CD11b, an anti-CD16, an anti-CD66b and an anti-CD66c antibodies may be mentioned. The antibody of the 10 second fluorescence-labeled antibody may bond to other cells such as monocytes, eosinophils, lymphocytes and the like provided that it bonds to the above-described antigen. As the antibody, a commercially available one may be used.

The antibody of the third fluorescence-labeled antibody 15 which bonds to immature granulocytic cells is an antibody capable of recognizing an antigen which exists on the surface of immature granulocytic cells in varying densities depending upon the degree of maturity of the immature granulocytic cells and bonding to the immature granulocytic cells. The type of the antibody is not particularly limited, provided that it bonds to one kind of or two or more kinds of promyelocytes, myelocytes, metamyelocytes and the like. For example, the anti-CD11b, anti-CD16, anti-CD66b and anti-CD66c antibodies may be mentioned. However, it is noted that the antibody of the third fluorescence-labeled antibody is required to 20 differ from that of the second fluorescence-labeled antibody used.

The antibody of the third fluorescence-labeled antibody may bond to other cells such as monocytes, eosinophils, lymphocytes and the like provided that it bonds to the above-described antigen.

In the present invention, the antibodies of the second and 5 third fluorescence-labeled antibodies may be any combination of the anti-CD16 antibody with the anti-CD11b antibody, the anti-CD16 antibody with the anti-CD66b antibody, the anti-CD16 antibody with the anti-CD66c antibody, the anti-CD11b antibody with the anti-CD66b antibody and the anti-CD11b antibody with the anti-CD66c antibody, for example. Among these combinations, the 10 combination of the anti-CD16 antibody and the anti-CD11b antibody is preferable.

As fluorescence-labeling compounds for the above-mentioned antibodies, labeling compounds such as fluorescein 15 isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin(APC), Texas Red, PE-CY5 and peridinin chlorophyll protein (PerCP) may be mentioned. The fluorescence-labeling compounds to be bonded to the three antibodies used in the present invention are required to have spectra different from each other. For example, a combination 20 of FITC, PE and PE-CY5 and a combination of FITC, PE and PerCP may be mentioned.

The mixture ratio of the fluorescence-labeled antibodies to the hematological sample may be adjusted as appropriate depending upon the state of the hematological sample, the types of the 25 fluorescence-labeled antibodies and the like. For example, the

5 mixture ratio (the antibodies: the hematological sample) by volume  
may be 1 : 20 to 1 : 2. Incubation temperature and incubation time  
at this step may be adjusted depending upon the mixture ratio of the  
fluorescence-labeled antibodies to the hematological sample and the  
10 like. For example, they may be allowed to incubate for 15 to 30  
minutes at room temperature or higher and for 30 to 40 minutes at  
lower temperature for instance 0 to 10°C. When the fluorescence-  
labeled antibodies are added to the hematological sample, the first,  
second and third fluorescence-labeled antibodies may be added to  
15 the hematological sample in this order or in any other order.

Alternatively, the first, second and third fluorescence-labeled  
antibodies may be mixed separately from the hematological sample  
and then the resulting mixture may be added to the hematological  
sample.

15 Erythrocytes are removed from the hematological sample.  
The removal of erythrocytes is carried out for purpose of avoiding  
effect of erythrocytes which may disturb measurement of leukocytes  
by flow cytometry in a later step. Erythrocytes may be removed  
from the hematological sample by treating the sample with dextran  
20 to precipitate erythrocytes, by treating the sample with a specific  
gravity liquid such as Ficoll-Hypaque to separate leukocytes from  
erythrocytes or by treating the sample with a reagent which gives  
damage to erythrocytes so as to lyse erythrocytes. Among such  
treatments, the treatment of the sample with an ammonium chloride  
25 based hemolysing agent for lysing erythrocytes is preferable because

this treatment is simple to operate and damages few leukocytes.

In step (1) of the present invention, erythrocytes may be removed from the hematological sample before leukocytes in the sample are stained with a fluorescence-labeled antibody, after the 5 leukocytes are stained with the fluorescence-labeled antibody, or between sub-steps of adding the first to third fluorescence-labeled antibodies to the sample, provided that the accomplishment of the later steps (3) to (6) which are described below is not affected adversely.

10 The flow cytometer used in step (2) is not particularly limited and any type of flow cytometer may be used. At least one signal representative of scattered light and three signals representative of fluorescence should be detected with regard to the above obtained hematological sample by the flow cytometer.

15 Scattered light generally measurable by flow cytometers includes forward scattered light (FSC) and side scattered light (SSC). In the present invention, the side scattered light is preferred since the side scattered light signal increases its intensity depending upon the size of a cell and the amount of granules and/or structures 20 contained in the cell. The fluorescence to be detected varies depending upon the types of labeling characteristics of the fluorescence-labeled antibodies used. For example, a combination of green fluorescence, orange fluorescence and red fluorescence may be mentioned.

25 In steps (3) to (5), immature granulocytes different in the

degree of maturity are classified and counted from at least one scattered light signal and three fluorescence signals.

First, in step (3), the group of granulocytic cells (including immature granulocytes and mature neutrophils and eosinophils) are identified on the basis of the intensity of the scattered light and the intensity of the fluorescence from the first fluorescence-labeled antibody. More particularly, the intensity of the scattered light and the intensity of the fluorescence from the first fluorescence-labeled antibody are measured and a two-dimensional distribution map (e.g., a scattergram) is produced with both the intensities plotted in two axes. Thereby, the group of granulocytic cells including immature granulocytes can be separated from monocytes, lymphocytes, basophils and debris which are erythrocytes remaining in the sample and/or pieces of erythrocytes destroyed by the hemolytic treatment (see Fig. 2).

In the two-dimensional distribution map, monocytes, lymphocytes, basophils and debris can be each identified as well as granulocytic cells including immature granulocytes as described above. Thereby the full leukocyte counts can be calculated by defining a group including the groups of all granulocytic cells including immature cells, monocytes, lymphocytes and basophils (see Fig. 1).

Subsequently, in step (4), the intensity of the fluorescence from the first fluorescence-labeled antibody and the fluorescence from the second or third fluorescence-labeled antibody are

measured in the identified group of granulocytic cells, thereby to identify the group of neutrophilic cells (mature neutrophils and immature granulocytes). For this measurement, the characteristic of eosinophils regarding antigen density can be utilized. For

5 example, if the anti-CD45 antibody and the anti-CD16 antibody are used as the first antibody and second antibody, mature neutrophils are positive to the anti-CD16 antibody while eosinophils and immature granulocytes are negative to the anti-CD16 antibody.

However eosinophils have a higher density of antigens to the anti-  
10 CD45 antibody than immature granulocytes. Therefore, by producing a two-dimensional distribution map with the intensity of the fluorescence from the first fluorescence-labeled antibody and the intensity of the fluorescence from the second fluorescence-labeled antibody plotted, neutrophils can easily be separated from  
15 eosinophils (see Fig. 3).

Further, in step (5), the intensities of the fluorescences from the second and third fluorescence-labeled antibodies are measured in the identified group of neutrophilic cells (mature neutrophils and immature granulocytes), thereby to identify  
20 immature granulocytes and further classify the immature granulocytes according to their degree of maturity. As the second and third antibodies used for this purpose, antibodies whose corresponding antigens change their expression according to the course of maturity of neutrophilic cells may be selected. However,  
25 for more effective classification according to the degree of maturity,

the antigens should preferably be different according to time of expression. For this reason, the second and third antibodies should preferably be a combination of the anti-CD16 antibody and the anti-CD11b antibody. More particularly, in the course of 5 maturation of neutrophilic cells, antigens CD16 and CD11b appear on the surface of the neutrophilic cells as the cells mature, but the time of expression of CD11b is earlier than that of CD16.

Accordingly, by using the anti-CD16 antibody and the anti-CD11b antibody as the second and third antibodies, respectively, and by 10 obtaining the two-dimensional distribution map with the intensity of the fluorescence from the second and third fluorescence-labeled antibodies plotted along the two axes of the scattergram, immature granulocytes can be separated from mature neutrophils on the basis of difference in the intensity of the fluorescence for the second 15 fluorescence-labeled antibody (see Fig. 4). Also the immature granulocytes can be classified into groups different in the degree of maturity on the basis of difference in the intensity of the fluorescence for the third fluorescence-labeled antibody (see Fig. 5).

Here, the classification of immature granulocytes into 20 groups different in the degree of maturity means that promyelocytes, myelocytes, metamyelocytes and the like are classified into at least two groups of immature granulocytes and cells in each group can be enumerated.

The total immature granulocyte count and the immature 25 granulocyte count in each of the groups different in the degree of

maturity thus obtained are divided by the total leukocyte count obtained in step (3) to obtain the ratio or proportional count for each of the immature granulocyte counts to the total leukocyte count.

5

## EXAMPLES

The method of classifying and counting immature granulocytes of the present invention is described in further detail by way of examples.

10 Example 1

Reagents having the following compositions were prepared:

① Fluorescence-labeled Antibodies

(a) PerCP-labeled anti-CD45 antibody (produced by Becton Dickinson, Anti-Hle-1, the first antibody having red fluorescence)

(b) FITC-fluorescence-labeled anti-CD16 antibody (produced by Becton Dickinson, Leu-11b, the second antibody having green fluorescence)

(c) PE-labeled anti-CD11b antibody (produced by Becton Dickinson, Leu-15, the third antibody having orange fluorescence)

20 ② Ammonium Chloride Base Hemolysing Agent

(d) Ammonium chloride ( $\text{NH}_4\text{Cl}$ ) 8.26g/L

(e) Potassium hydrogencarbonate ( $\text{KHCO}_3$ ) 1.0g/L

(f) EDTA-4Na 0.037g/L

(g) Purified water

25

Ten  $\mu$  L of the FITC-labeled anti-CD16 antibody, 10  $\mu$  L of the PE-labeled anti-CD11b antibody and 10  $\mu$  L of the PerCP-labeled anti-CD45 antibody were added to 100  $\mu$  L of peripheral blood anticoagulated with heparin. The resulting mixture was incubated 5 for about 30 minutes at room temperature to fluorescence-stain leukocytes.

Then 2mL of the ammonium chloride base hemolysing agent were added to the mixture, which was then incubated for five minutes at room temperature, thereby to hemolyse and remove 10 erythrocytes which would disturb measurement of leukocytes.

Side scattered light and fluorescences having wavelengths of 530 nm (green), 585nm (orange) and 650 nm (red) were measured with regard to the thus obtained hematological sample using a flow cytometer provided with an argon ion laser of 488nm as a light 15 source.

Fig. 6 shows a scattergram with the intensity of the side scattered light and the intensity of the red fluorescence plotted in the coordinate axes, illustrating the distribution of cells in the sample. Five groups of granulocytes, monocytes, lymphocytes, 20 basophils and debris were recognized as seen in Fig. 6. Analysis was made by enclosing all leukocytes with a window W1 and counting the total number of the enclosed leukocytes (see Fig. 7).

Also, granulocytes were enclosed within a window W2 in the same scattergram (see Fig. 7).

25 Fig. 8 shows a scattergram with the intensity of the red

fluorescence and that of the green fluorescence plotted in the coordinate axes, illustrating the distribution only of cells in window W2.

Three groups of eosinophils, immature granulocytes and 5 mature neutrophils were recognized as seen in Fig. 8. Analysis was made by enclosing neutrophilic cells (immature granulocytes and mature neutrophils) within a window W3 as shown in Fig. 8.

Fig. 9 shows a scattergram with the intensity of the orange 10 fluorescent light and that of the green fluorescent light plotted in the coordinate axes, illustrating the distribution only of cells in window W3.

Three groups of immature granulocytes in a stage I, 15 immature granulocytes in a stage II and mature neutrophils were recognized as seen in Fig. 9. Analysis was made by enclosing the two groups of immature granulocytes within a window W4 and counting the total number of the immature granulocytes.

Next, the total number of immature granulocytes was divided by the total number of the leukocytes counted above, thereby to obtain the ratio or proportional count of the immature 20 granulocyte count to the total leukocyte count.

Separately from Example 1, immature granulocytes were analyzed by a manual microscopic method (May-Grünwald-Giemsa stain or other appropriate blood film stain, 800 WBC count) with use of a hematological sample which was substantially the same as used 25 in Example 1.

Fig. 10 is a graph showing correlation between the ratio or proportional count of the immature granulocytes count obtained with the flow cytometer in Example 1 and that obtained by the manual microscopic method.

5 As shown in Fig. 10, a correlation coefficient of  $r^2=0.87$  and regression analysis of  $y=1.13x + 1.04$  was obtained, which showed that the method of Example 1 was remarkably accurate in classifying and counting immature granulocytes.

Example 2

10 Immature granulocytes in peripheral blood were measured by the same method as in Example 1. Analysis was made by enclosing the two groups of immature granulocytes with separate windows W5 and W6, counting the numbers of stage-I immature granulocytes in window W5 and stage-II immature granulocytes in 15 window W6 and obtaining the ratios of the stage-I and stage-II immature granulocyte counts to the total leukocyte count.

Separately from Example 2, immature granulocytes of each type were analyzed by a manual microscopic method (May-Grünwald-Giemsa stain) with use of a hematological sample 20 substantially the same as used in Example 2. Additionally, the stage-I immature granulocytes identified by the method of the invention correspond to promyelocytes and myelocytes identified by the manual microscopic method and the stage-II immature granulocytes identified by the method of the invention correspond to 25 metamyelocytes identified by the manual microscopic method.

Fig. 12 is a graph showing correlation between the ratio of the stage-I immature granulocyte count obtained with the flow cytometer in Example 2 and that obtained by the manual microscopic method. Fig. 13 is a graph showing correlation 5 between the ratio of the stage-II immature granulocyte count obtained with the flow cytometer in Example 2 and that obtained by the manual microscopic method.

As regards the stage-I immature granulocytes, the correlation coefficient of  $r^2=0.87$  and regression analysis of  $y=0.93x + 0.47$  was obtained as shown in Fig. 12, and as regards the stage-II immature granulocytes, the correlation coefficient of  $r^2=0.80$  and regression analysis of  $y=1.39x + 0.62$  was obtained as shown in Fig. 13. These results showed that the method of Example 2 is remarkably accurate in classifying and counting immature 15 granulocytes in each stage of maturity.

**What is claimed is:**

1. A method for classifying and counting leukocytes comprising the steps of:
  - (1) adding to a hematological sample the following 5 fluorescence-labeled antibodies labeled with fluorescent dyes which emit fluorescences distinguishable from each other;
    - (a) a first fluorescence-labeled antibody which bonds specifically to leukocytes,
    - (b) a second fluorescence-labeled antibody which bonds to 10 at least one kind of neutrophilic cells, and
    - (c) a third fluorescence-labeled antibody which bonds to at least one kind of immature granulocytic cells, in order to stain leukocytic cells in the hematological sample, and
  - 15 removing erythrocytes from the hematological sample;
- (2) analyzing the resulting hematological sample using a flow cytometer to measure at least one scattered light signal and three separate fluorescence signals;
- (3) defining a group of granulocytic cells on the basis of 20 intensity of the scattered light and intensity of fluorescence from the first fluorescence-labeled antibody;
- (4) defining neutrophilic cells in the defined group of granulocytic cells on the basis of the intensity of the fluorescence from the first fluorescence-labeled antibody and intensity of 25 fluorescence from the second or third fluorescence-labeled antibody;

(5) classifying the defined group of the neutrophilic cells into groups of neutrophilic cells different in degree of maturity on the basis of the intensity of the fluorescence from the second fluorescence-labeled antibody and the intensity of the fluorescence

5 from the third fluorescence-labeled antibody, and

counting the number of cells in each of the groups.

2. A method according to claim 1, wherein in step (3), a group of all leukocytic cells is defined and counted on the basis of the intensity of the scattered light and the intensity of the fluorescence from the first fluorescence-labeled antibody in addition to the group of granulocytic cells, and in step (5), the ratio of the number of the neutrophilic cells in each of the groups different in degree of maturity with respect to the number of all the leukocytic cells is calculated.

15 3. A method according to claim 1, wherein the first fluorescence-labeled antibody comprises an anti-CD45 antibody.

4. A method according to claim 1, wherein the second fluorescence-labeled antibody comprises an antibody selected from the group consisting of an anti-CD11b antibody, an anti-CD16 antibody, an anti-CD66b antibody and an anti-CD66c antibody, and the third fluorescence-labeled antibody comprises an antibody selected from the same group but different from the antibody of the second fluorescence-labeled antibody.

20 5. A method according to claim 1, wherein the second and third fluorescence-labeled antibodies comprises any combination of

an anti-CD16 antibody with an anti-CD11b antibody, an anti-CD16 antibody with an anti-CD66b antibody, an anti-CD16 antibody with an anti-CD66c antibody, an anti-CD11b antibody with an anti-CD66b antibody, and an anti-CD11b antibody with an anti-CD66c antibody.

5 antibody.

6. A method according to claim 5, wherein the second and third fluorescence-labeled antibodies comprise the anti-CD16 antibody and the anti-CD11b antibody.

7. A method according to claim 1, wherein the scattered light 10 measured is side scattered light.

8. A method according to claim 1, wherein the fluorescent dyes are selected from the group consisting of fluorescein isothiocyanate (FITC), phycoerythrin (PE), allophycocyanin (APC), Texas Red, PE-CY5 and peridinin chlorophyll protein (PerCP).

15 9. A method according to claim 7, wherein the fluorescent dyes of the first, second and third fluorescence-labeled antibodies for emitting distinguishable fluorescences comprise a combination of FITC, PE and PE-CY5 or a combination of FITC, PE and PerCP.

10. A method according to claim 1, wherein the hematological 20 sample is a sample of peripheral blood, bone marrow fluid or urine of a mammal or a sample collected from a mammal by apheresis.

11. A method according to claim 1, wherein in step (1), the leukocytic cells are fluorescence-stained after erythrocytes are removed from the hematological sample.

## **ABSTRACT OF THE DISCLOSURE**

A method for classifying and counting leukocytes comprises the steps of: (1) adding to a hematological sample the following fluorescence-labeled antibodies labeled with fluorescent dyes which


5 emit fluorescences distinguishable from each other; (a) a first fluorescence-labeled antibody (1st antibody) which bonds specifically to leukocytes, (b) a second fluorescence-labeled antibody (2nd antibody) which bonds to at least one kind of neutrophilic cells, and (c) a third fluorescence-labeled antibody (3rd antibody) which

10 bonds to at least one kind of immature granulocytic cells, in order to stain leukocytic cells in the sample, and removing erythrocytes from the sample; (2) analyzing the resulting sample using a flow cytometer to measure at least one scattered light signal and three separate fluorescence signals; (3) defining a group of granulocytic


15 cells on the basis of intensity of the scattered light and intensity of fluorescence from the 1st antibody; (4) defining neutrophilic cells in the defined group of granulocytic cells on the basis of the intensity of the fluorescence from the 1st antibody and intensity of fluorescence from the 2nd or 3rd antibody; (5) classifying the defined group of the

20 neutrophilic cells into groups of neutrophilic cells different in degree of maturity on the basis of the intensity of the fluorescence from the 2nd antibody and the intensity of the fluorescence from the 3rd antibody, and counting the number of cells in each of the groups.


**FIG. 1**




**FIG. 2**




**FIG. 3**




**FIG. 4**




**FIG. 5**




**FIG. 6**




**FIG. 7**




**FIG. 8**




**FIG. 9**




**FIG. 10**



**FIG. 11**



**FIG. 12**



**FIG. 13**

